News

Press Releases

November 23, 2020
Merck to Acquire OncoImmune

KENILWORTH, N.J., & ROCKVILLE, Md.–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, […]

Read more
September 23, 2020
OncoImmune Launches First-in-human Clinical Trial for ONC-392

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, […]

Read more
December 30, 2019
OncoImmune Announces Approval of IND Application for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy

OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has […]

Read more
Scroll to Top